$0.8533
-0.021-2.4%
Last update: Nov 12, 8:15 AM
Annovis Bio Inc (ANVS) Stock Price, Quote, News & History
ANVSNYSE
Annovis Bio rises after Phase 3 data show buntanetap halted decline in Parkinson's patients, with results in those with amyloid co-pathology.
You can purchase shares of Annovis Bio (NYSE:ANVS) through any online brokerage.
Other companies in Annovis Bio’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Annovis Bio has a consensus price target of $27.88.
The stock price for Annovis Bio (NYSE: ANVS) is $0.815 last updated November 12, 2026 at 8:15 AM EST.
There are no upcoming dividends for Annovis Bio.
Annovis Bio does not have any upcoming earnings scheduled.
There is no upcoming split for Annovis Bio.
Annovis Bio is in the Health Care sector and Biotechnology industry. They are listed on the NYSE.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's...
